Seattle Genetics Reports Added Analyses From Phase 3 ECHELON-1 Trial Of ADCETRIS In Newly-Diagnosed Advanced Hodgkin Lymphoma At ASCO: Data Continues To Support Superior Clinical Activity Of ADCETRIS In Combo vs ABVD In Frontline Advanced Hodgkin Lymphoma